Physician profile
Eugene Long
$604.28
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.20 · 2020: $28.31 · 2021: $75.22 · 2022: $107 · 2023: $331 · 2024: $24.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $175.07 | 2022-2023 | Pomalyst, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $109.72 | 2019-2022 | |
| Seagen INC. | $76.81 | 2022-2023 | Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $60.36 | 2022-2023 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $60.17 | 2022-2023 | Ninlaro |
| Dendreon Pharmaceuticals LLC | $24.32 | 2024 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $19.40 | 2023 | Imbruvica |
| Glaxosmithkline, LLC. | $18.07 | 2023 | Zejula, Jemperli |
| Genentech USA, INC. | $17.39 | 2021 | |
| Merck Sharp & Dohme LLC | $15.95 | 2020 | |
| Abbvie INC. | $14.21 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.